Research & Development
MG Biotherapeutics has a vibrant collaborative research program being carried out through the parent corporations. Knowledge gained through the MGB research collaboration will be important to bringing innovative device-biologic combination therapies to patients suffering from serious heart disease. The focus of this research is an investigation of “next generation” cell therapies for heart disease. Research within the collaboration has revealed potential key areas for significantly improving the efficacy and ease-of-use of cells for cardiac repair and regeneration. Specifically, we are focusing our attention on mechanisms to improve the retention of cells delivered to the heart via percutaneous methods, and on ways to increase the bioactivity of injected cells. Recent publications have highlighted the role played by locally secreted protein factors in preserving myocardial tissue during ischemic stress and in calling in cells to the site of injury that participate in the angiogenesis process. Use of biomaterials offers the potential to control the dose of cells delivered and acutely retained in the heart, and when coupled with cellular modifications that increase the secretion of therapeutic proteins may greatly enhance cell therapy efficacy during the subacute infarction timeframe or in the “no-option” patient.
|
|
|
MG Biotherapeutics Home
